



Illumina, Inc
NR200647

ILLUMINA TO DEVELOP iSELECT BOVINE BEADCHIP WITH THREE COLLABORATING INSTITUTIONS TO GENOTYPE OVER 10,000 CATTLE

Genome-Wide SNP Content Designed to Improve Selection for Multiple Breeds of Cattle

SAN DIEGO, CALIFORNIA, August 24, 2006 -- Illumina, Inc. (NASDAQ: ILMN) announced today that it has signed a commercial agreement to develop a new multi-sample Bovine BeadChip that uses the Infinium™ assay to initially genotype over 10,000 cattle. Illumina's recently released iSelect genotyping BeadChip allows the analysis of twelve samples in parallel with over 48,000 SNP markers per sample, on a single microarray. SNP content will be developed in close collaboration with scientists at three organizations: the United States Department of Agriculture (USDA) Agricultural Research Service (ARS), the University of Missouri-Columbia (MU) and the University of Alberta (UA). The SNP content will utilize the release of the bovine draft sequence and recent genome assembly (Btau 3.0) done at the Baylor College of Medicine. The SNP markers will be used by the participants to map quantitative trait loci (QTLs) and to selectively breed cattle. Following development of the new Bovine BeadChip and analysis of the initial batch of samples, Illumina plans to offer the new product in early 2007 as a standard catalog array that can be purchased and used by any customer.

Drs. Curt Van Tassell and Tad Sonstegard (USDA), Jerry Taylor (MU) and Stephen Moore (UA) are guiding the SNP content selection and are leading the Infinium genotyping efforts at their respective organizations. Collectively, the organizations will genotype over 10,000 cattle samples representing at least 10 different breeds.

“With the recent release of the Bovine genome assembly and sequence, the development of a high-quality comprehensive bovine SNP array is the next critical step,” stated University of Alberta's Dr. Moore. “My colleagues and I are very excited to collaborate with Illumina on the development of such an important bovine array. With Illumina, we will be able to take advantage of the most complete genetic map of the bovine genome to date to provide an optimized SNP array to the bovine genomics community. DNA differences detected through genotyping will expand gene discovery for better meat and milk production and quality, enable modeling of human disease and

will shed light on the relationships between different populations of animals. This will be an invaluable contributing tool combined with the recent sequence release for genetics and genomics research in agriculture and medicine.”

Dr. Taylor (MU) commented further, "Outbred populations of domestic cattle have the most extensively recorded pedigree and phenotype histories of any of mankind's close relatives. This wealth of information is an untapped reservoir with the potential for immense benefits to the health and well-being of our species. Illumina's iSelect Bovine BeadChip will help tap this resource with a phenomenal range of applications across the scientific spectrum which will include elucidating the history of domestication of cattle and their close relatives, examining the evolution of genomes under strong selection and, of course, the discovery of elements responsible for phenotypic variation in disease, growth and development."

According to Jay Flatley, Illumina President and CEO, “We’re very pleased to be able to work with such a remarkable group of investigators who share a single vision. We believe this collaborative effort will result in a tool of significant value to the cattle breeding community and serve as an instructive model for improved breeding of other agricultural species.”

More information about the organizations and investigators conducting the bovine study can be found at the following sites: <http://www.ars.usda.gov> (United States Department of Agriculture), <http://animalgenomics.missouri.edu/> (University of Missouri) and <http://www.ifasa.afhe.ualberta.ca/> (University of Alberta).

About Illumina

Illumina (www.illumina.com) develops and markets next-generation tools for the large-scale analysis of genetic variation and function. The Company's proprietary BeadArray technology -- used in leading genomics centers around the world -- provides the throughput, cost effectiveness and flexibility necessary to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics and proteomics. This information will help pave the way to personalized medicine by correlating genetic variation and gene function with particular disease states, enhancing drug

discovery, allowing diseases to be detected earlier and more specifically, and permitting better choices of drugs for individual patients.

Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: this release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are the costs and outcome of Illumina’s litigation with Affymetrix, the Company’s ability to scale and integrate CyVera technology, the ability to further scale oligo synthesis output and technology to satisfy market demand deriving from the Company’s collaboration with Invitrogen, Illumina’s ability to further develop and commercialize its BeadArray technologies and to deploy new gene expression and genotyping products and applications for its platform technology, to manufacture robust Sentrix[®] arrays – including HumanHap BeadChips -- and Oligator[®] oligonucleotides, and other factors detailed in the Company’s filings with the Securities and Exchange Commission including its recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. Illumina disclaims any intent or obligation to update these forward-looking statements beyond the date of this release.

###

Contacts: Jay Flatley
President & CEO
Illumina, Inc.
+1 858 202.4501
jflatley@illumina.com

Karen Possemato
Associate Director of Marketing
Illumina, Inc.
+1 858 202.4575
kpossemato@illumina.com